Team Strategies for Overcoming Challenges to Guideline-Concordant Care of High-Risk HR-Positive/HER2-Negative Early Breast Cancer

Click the Register/Take Course button to complete the evaluation and get your certificate.

This activity aims to improve learners’ knowledge and competence at integrating CDK4/6 inhibitors into practice to improve clinical outcomes in patients with HR-positive/HER2-negative early breast cancer.

Provided by National Comprehensive Cancer Network (NCCN) in collaboration with Decera Clinical Education.

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR-positive/HER2-negative early breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Collaborate with multidisciplinary colleagues to identify each patient with HR-positive/HER2-negative EBC who is eligible for CDK4/6 inhibitor treatment
  • Recommend the optimal CDK4/6 inhibitor treatment for each patient with HR-positive/HER2-negative EBC in alignment with NCCN Guidelines, high-level evidence, and expert-recommended best practices
  • Support open and frequent patient-clinician communication to enable effective counseling on the benefits vs potential risks of adjuvant CDK4/6 inhibitor treatment, reporting of patient-felt toxicities, and screening for barriers to adherence/persistence
  • Implement proactive toxicity monitoring, dose modification, and supportive care to enable patient adherence and persistence to CDK4/6 inhibitor treatment for HR-positive/HER2-negative EBC

You may also be interested in

Recorded Presentations from the NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium

The NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium offers expert insights into current recommendations of care for patients with breast cancer and highlights the latest clinical research updates to assist clinicians in formulating breast c
Additional information
Supporters: 

This activity is supported by educational grants from Lilly and Novartis.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ABIM Medical Knowledge
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Course opens: 
03/30/2026
Course expires: 
12/31/2026

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Full disclosure of faculty relationships will be made prior to the activity.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. This program offers 1.0 pharmacotherapeutic contact hour for nurses.

Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: TBD

Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to ABIM via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ABIM Medical Knowledge
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Please login or register to take this course.

Click the Register/Take Course button to complete the evaluation and get your certificate.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing